Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ries

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Current Opinion in Pharmacology|June 9, 2015
CSF-1/CSF-1R targeting agents in clinical development for cancer therapyCarola H Ries, Sabine Hoves, Michael A Cannarile, et al.
The FEBS Journal|September 24, 2017
A drug development perspective on targeting tumor-associated myeloid cellsMeher Majety, Valeria Runza, Christian Lehmann, et al.
Chest|February 1, 1994
Pulmonary aspiration in mechanically ventilated patients with tracheostomiesE H Elpern, M G Scott, L Petro, et al.
Journal for Immunotherapy of Cancer|July 19, 2017
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapyMichael A Cannarile, Martin Weisser, Wolfgang Jacob, et al.
Frontiers in Immunology|October 5, 2020
The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse ModelsIlona-Petra Maser, Sabine Hoves, Christa Bayer, et al.
Hepatology (Baltimore, Md.)|April 20, 2019
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular CarcinomaCarina Hage, Sabine Hoves, Léanne Strauss, et al.
Cell Reports|March 8, 2018
Periostin Limits Tumor Response to VEGFA InhibitionIoanna Keklikoglou, Ece Kadioglu, Stefan Bissinger, et al.
Molecular Cancer Therapeutics|September 2, 2016
Macrophage Susceptibility to Emactuzumab (RG7155) TreatmentLeon P Pradel, Chia-Huey Ooi, Solange Romagnoli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2018
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor ResponsesRafael Cubas, Marina Moskalenko, Jeanne Cheung, et al.
Cancer Immunology Research|July 15, 2020
CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated MannerMarine M Leblond, Laure Tillé, Sina Nassiri, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Current Opinion in Pharmacology|June 9, 2015
CSF-1/CSF-1R targeting agents in clinical development for cancer therapyCarola H Ries, Sabine Hoves, Michael A Cannarile, et al.
The FEBS Journal|September 24, 2017
A drug development perspective on targeting tumor-associated myeloid cellsMeher Majety, Valeria Runza, Christian Lehmann, et al.
Chest|February 1, 1994
Pulmonary aspiration in mechanically ventilated patients with tracheostomiesE H Elpern, M G Scott, L Petro, et al.
Journal for Immunotherapy of Cancer|July 19, 2017
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapyMichael A Cannarile, Martin Weisser, Wolfgang Jacob, et al.
Frontiers in Immunology|October 5, 2020
The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse ModelsIlona-Petra Maser, Sabine Hoves, Christa Bayer, et al.
Hepatology (Baltimore, Md.)|April 20, 2019
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular CarcinomaCarina Hage, Sabine Hoves, Léanne Strauss, et al.
Cell Reports|March 8, 2018
Periostin Limits Tumor Response to VEGFA InhibitionIoanna Keklikoglou, Ece Kadioglu, Stefan Bissinger, et al.
Molecular Cancer Therapeutics|September 2, 2016
Macrophage Susceptibility to Emactuzumab (RG7155) TreatmentLeon P Pradel, Chia-Huey Ooi, Solange Romagnoli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2018
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor ResponsesRafael Cubas, Marina Moskalenko, Jeanne Cheung, et al.
Cancer Immunology Research|July 15, 2020
CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated MannerMarine M Leblond, Laure Tillé, Sina Nassiri, et al.
Pageof 6